Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
Provided By GlobeNewswire
Last update: Dec 23, 2024
Blarcamesine: Potential novel oral treatment to target upstream Alzheimer’s disease pathology through autophagy enhancement
Submission based on favorable ANAVEX®2-73-AD-004 trial results in patients with early Alzheimer’s disease
Read more at globenewswire.com
